Recursion Pharmaceuticals ( (RXRX) ) has issued an update.
Recursion, a tech-driven biopharmaceutical company, is making strides in its drug discovery pipeline with significant clinical trial milestones and expanding partnerships. Highlights include promising Phase 2 trial data in cerebral cavernous malformation, a new collaboration with Google Cloud, and a potential merger with Exscientia. Despite a net loss, Recursion’s revenue jumped due to partnerships with Roche-Genentech, emphasizing its robust tech-enabled discovery platform. The company remains optimistic about creating transformative therapies and expanding its technological capabilities.
Learn more about RXRX stock on TipRanks’ Stock Analysis page.
